专利检索 ap:("BOEHRINGER INGELHEIM PHARMACEUTICALS INC.") AND inv:"PARKS, Thomas, P." 第 1 页

1.

发明授权
4-SUBSTITUTED BETA-CARBOLINES AS IMMUNOMODULATORS 失效
标题翻译： 4-取代的β-咔啉作为免疫调节剂

公开(公告)号：EP0923581B1

公开(公告)日：2003-05-21

申请号：EP97938122.5

申请日：1997-08-08

申请人： BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

发明人： HARGRAVE, Karl, D. , MIAO, Clara, K. , PARKS, Thomas, P. , POTOCKI, Ian, F. , SNOW, Roger, J.

IPC分类号： C07D471/04 , A61K31/44

CPC分类号： C07D471/04 , A61K31/437 , A61K31/444

摘要： This invention relates to 4-substituted β-carbolines and β-carboline analogs that inhibit Ca+2 influx and interleukin-2 (IL-2) production. The 4-substituted β-carbolines and β-carboline analogs of this invention are represented by formula (I) wherein Q, n, R, R', R'' and R¿1?-R4 are as defined herein. This invention also relates to methods for producing β-carbolines. Because of their selective immunomodulating properties, the compounds and pharmaceutical compositions of this invention are particularly well suited for preventing and treating immune disorders, including autoimmune disease, inflammatory disease, organ transplant rejection and other disorders associated with IL-2 mediated immune response.

2.

发明公开
4-SUBSTITUTED BETA-CARBOLINES AS IMMUNOMODULATORS 失效
标题翻译： 4-取代的β-咔啉作为免疫调节剂

公开(公告)号：EP0923581A1

公开(公告)日：1999-06-23

申请号：EP97938122.0

申请日：1997-08-08

申请人： BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

发明人： HARGRAVE, Karl, D. , MIAO, Clara, K. , PARKS, Thomas, P. , POTOCKI, Ian, F. , SNOW, Roger, J.

IPC分类号： C07D491 , A61K31 , A61P37 , C07D471 , C07D495

CPC分类号： C07D471/04 , A61K31/437 , A61K31/444

摘要： This invention relates to 4-substituted β-carbolines and β-carboline analogs that inhibit Ca+2 influx and interleukin-2 (IL-2) production. The 4-substituted β-carbolines and β-carboline analogs of this invention are represented by formula (I) wherein Q, n, R, R', R'' and R¿1?-R4 are as defined herein. This invention also relates to methods for producing β-carbolines. Because of their selective immunomodulating properties, the compounds and pharmaceutical compositions of this invention are particularly well suited for preventing and treating immune disorders, including autoimmune disease, inflammatory disease, organ transplant rejection and other disorders associated with IL-2 mediated immune response.